Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals presented groundbreaking preclinical data on HER3-targeted radiotherapy at the AACR 2023 Annual Meeting, reporting a significant reduction in tumor volume (p<0.0001) for ovarian cancer when conjugated to Actinium-225 or Lutetium-177, outperforming bevacizumab.
The HER3 target is frequently overexpressed in various solid tumors and linked to poor survival rates. The results indicated effective target engagement and cytotoxic activity in preclinical models for both ovarian and colorectal cancers.
Actinium aims to address high unmet medical needs, highlighting the potential for broad application in different oncology indications. The data showcases Actinium's innovative approach, reaffirming its commitment to developing efficient targeted therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) recently showcased promising data on Actimab-A, a targeted radiotherapy, at the AACR 2023 Annual Meeting in Orlando, Florida. The data highlights Actimab-A's ability to effectively deplete myeloid derived suppressor cells (MDSCs), which are known to inhibit immune responses in various cancers. Key findings include:
- Actimab-A demonstrated superior effectiveness in depleting MDSCs compared to other treatments like Mylotarg.
- Data supported its potential as a backbone therapy to enhance the efficacy of immunotherapies across multiple solid tumor types.
- The treatment showed promise in boosting the antitumor activity of immunotherapies, including checkpoint inhibitors.
Actinium is actively pursuing further development of Actimab-A, aiming to leverage its capabilities in combination therapies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in relapsed/refractory acute myeloid leukemia (r/r AML) patients aged 55 and older, achieving a durable complete remission (dCR) rate of 75% (44/59 patients) and doubling overall survival at 1 year compared to the control arm. The company plans to submit a Biologics License Application (BLA) for Iomab-B in the second half of 2023 and is launching an Early Access Program. Actimab-A also demonstrated promising 1-year survival rates in a trial subset. With a strong financial position of $108.9 million, Actinium aims to fund operations through 2025.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
